In particular, since few studies investigated the role of polymorphism rs5219 in the KCNJ11 gene in therapeutic response to sulphonylureas [9] or hypoglycemia risk [29], we inferred that this SNP falls in a PPARγ binding site and within a CpG island located in the gene body, possibly linking such variant to altered KCNJ11 expression. The gene discussed is KCNJ11; the disease is Hypoglycemia.